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Background: T cell immunoglobulin and mucin domain con-
taining 3 protein (Tim-3) expressed on terminally differ-
entiated Th1 cells plays a suppressive role in Th1-mediated 
immune responses. Recently, it has been shown that N-gly-
cosylation affects the binding activity of the Tim-3-Ig fusion 
protein to its ligand, galectin-9, but the binding properties of 
non-glycosylated Tim-3 on CD4
＋CD25
＋ T cells has not been 
fully examined. In this study, we produced recombinant Tim- 
3-Ig fusion proteins in different cellular sources and its N-gly-
cosylation mutant forms to evaluate their binding activities to 
CD4
＋CD25
＋ T cells. Methods: We isolated and cloned Tim- 
3 cDNA from BALB/C mouse splenocytes. Then, we con-
structed a mammalian expression vector and a prokaryotic 
expression vector for the Tim-3-Ig fusion protein. Using a site 
directed mutagenesis method, plasmid vectors for Tim-3-Ig 
N-glycosylation mutant expression were produced. The re-
combinant protein was purified by protein A sepharose col-
umn chromatography. The binding activity of Tim-3-Ig fusion 
protein to CD4
＋CD25
＋ T cells was analyzed using flow 
cytometry. Results: We found that the nonglycosylated Tim- 
3-Ig fusion proteins expressed in bacteria bound to CD4
＋ 
CD25
＋ T cells similarly to the glycosylated Tim-3-Ig protein 
produced in CHO cells. Further, three N-glycosylation mu-
tant forms (N53Q, N100Q, N53/100Q) of Tim-3-Ig showed 
similar binding activities to those of wild type glycosylated 
Tim-3-Ig.  Conclusion: Our results suggest that N-glyco-
sylation of Tim-3 may not affect its binding activity to ligands 
expressed on CD4
＋CD25
＋ T cells. 
[Immune Network 2009;9(2):58-63]
INTRODUCTION
T cell immunoglobulin and mucin domain containing 3 pro-
tein (Tim-3) was identified using monoclonal antibodies spe-
cific to TH1-cell clones (1). Tim-3 is expressed on the surface 
o f  d i f f e r e n t i a t e d  T H 1  c e l l s ,  C D 8  T  c e l l s  a n d  s o m e  m a c r o -
phages (2). Also, Tim-3 expression in mast cells and NK cells 
has been recently demonstrated (2,3). Tim-3 belongs to the 
TIM family of genes because it contains an immunoglobulin 
( I g )  V - l i k e  d o m a i n  a n d  a  m u c i n - l i k e  d o m a i n  ( 4 ) .
    The function of Tim-3 has been revealed using antibodies 
against Tim-3 and Tim-3-Ig fusion proteins. Administration of 
Tim-3  blocking  antibody  aggravates  experimental  autoim-
mune encephalitis (1). Injection of Tim-3-Ig into mice induces 
hyperproliferation of TH1 cells as well as TH1 cytokine re-
lease  and  abrogated  tolerance  induction  in  TH1  cells  (2). 
Blocking antibody against Tim-3 accelerated autoimmune dia-
betes partly due  to the  hindrance  of the  function  of  CD4
＋ 
CD25
＋ regulatory T cells (5). Further, injection of Tim-3 anti-
body  into  coxsackievirus-infected  mice  exacerbates  cardiac 
inflammation  and  reduces  expression  of  CTLA-4  on  T  cells 
and  B7.1  on  APCs  (6).  The  treatment  with  Tim-3  antibody 
enhanced interferon-γ  expression and cytotoxicity by donor 
CD8+ T cells against host alloantigen, resulting in accelerated 
acute  graft  versus  host  disease  in  mice  (7).
    As  a  Tim-3  ligand,  galectin-9  was  identified  from  a  CD8 
T cell clone that showed a Tim-3 binding profile on flow cy-
tometric analysis (8). Interaction of galectin-9 with Tim-3 re-
quires carbohydrate motif(s) on Tim-3IgV (8). A soluble iso-
form (sTim-3-Ig), containing the IgV domain but lacking the 
mucin domain binds to galectin-9 (8). Further, in coprecipita-
tion  experiments  with  untreated  or  N-glycosidase  F-treated 
(deglycosylated)  sTim-3-Ig  and  galectin-9,  only  untreated 
sTim-3-Ig was able to precipitate galectin-9, implying that the 
carbohydrates on the sTim-3-Ig bind to galectin-9 (8). N-gly-
cosidase F removes unaltered most of the common N-linked The Ligand Binding Activity of Recombinant Tim-3
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carbohydrates from proteins while hydrolyzing the originally 
glycosylated  Asn  residue  to  Asp  (9).
    N-glycosylation consensus sequence, Asn-Xaa-Ser/Thr, oc-
currs twice in Tim-3 IgV like domain. Even before the identi-
fication of galectin-9 as a Tim-3 ligand, the importance of IgV 
domain  for  ligand  binding  was  revealed  by  demonstrating   
putative ligand(s) expression of CD4
＋CD25
＋ T cells using re-
combinant  Tim-3  IgV  protein  (10).  Although  galectin-9  ex-
pression in regulatory T cells has not yet been demonstrated, 
in vivo  administration  of galectin-9  leads selective  TH1  cell 
deletion and promotion of regulatory T cell induction (11). 
Despite the importance of N-linked glycosylation of the IgV 
domain of Tim-3 in its ligand binding activity, it has not been 
directly examined whether glycosylation of these sequences 
is involved in binding to ligands expressed on CD4
＋CD25
＋ 
T cells. In this study, we produced recombinant Tim-3-Ig fu-
sion  proteins  in  different  cellular  sources  and  its  N-glyco-
sylation mutant forms. We evaluated their binding activities 
to  CD4
＋CD25
＋ T  c e l l s .
MATERIALS AND METHODS
Construction of plasmids for Tim-3-Ig fusion protein 
expression 
The  Tim-3 gene  was  cloned from  splenocytes of a BALB/c 
mouse. First, splenocytes (1×10
6) were stimulated with Con-
canavalin A (1 ug/ml) for 2 days, and then, total RNA was 
extracted by RNA-Bee RNA isolation reagent (Tel-Test, Frie-
ndswood, TX, USA). Total RNA was subjected to reverse tran-
scription  using  RNase  H-  reverse  transcriptase  (Invitrogen, 
Carsbade, CA, USA). The cDNA was amplified using Tim-3 
specific  primers  (2).  The  PCR  products  were  cloned  into 
pCR2.1-TOPO vector (Invitrogen) and sequenced. Tim-3 gene 
sequences were registered in NCBI database. The gene en-
coding the extracellular domain of Tim-3 was amplified with 
specific  primers  (Tim-3-Forward  (NheI))  :GCTAGCATGTTT 
TCAGGTCTTACCCTCAACTGTG  and  Tim-3-Reverse  (BglII)) 
:AGATCTTCTGATCGTTTCTCCAGAGTCCTTAATTTCATCAG), 
and the PCR product was inserted into pIRES2-EGFP vector 
(Clontech) using the NheI and BglII site. The gene encoding 
IgG1  heavy  chain  CH2CH3  was  amplified  using  pTOPO- 
hIgG1 vector (kind gift of Dr. Kwon, Ajou University, Korea) 
and the specific primers (HIgC-Foward(BglII)): GAAGATCTG 
CACCTGAACTCCTGGGG and HIgC-Reverse(BamHI)): CGGG 
ATCCTCATTTACCCTGCGACAG). Using the BglII and EcoRI 
site,  the  PCR  product  was  ligated  to  pIRES2-EGFP  down-
stream of Tim-3 gene. To construct prokaryotic Tim-3-Ig ex-
pression vector, Tim-3-Ig DNA fragment was subcloned into 
pIg20 vector using  XmaI and NcoI. To produce expression 
vectors  for  N-glycosylation  mutant  Tim-3-Ig,  the  Arg53  and 
100Arg  of  Tim-3  were  replaced  to  glutamine  using  site  di-
rected mutagenesis kit (Clontech) and pIRES-EGFP-Tim-3-Ig. 
The  nucleotide  sequences  were  verified.
Purification of Tim-3-Ig
In order to produce CD4
＋ Tim-3-Ig protein, Chinese hamster 
ovary  (CHO)  cells  were  transfected  with  pIRES2-EGFP-Tim- 
3-Ig  vector  using  Polyethylenimine  (PEI,  Polyscience,  PA 
USA). After 2 days, the culture supernatant was harvested and 
T i m - 3 - I g  w a s  p u r i f i e d  u s i n g  p r o t e i n  A  s e p h a r o s e  c o l u m n  
(Amersham  Biosciences,  Uppsala,  Sweden).  The  purity  of 
Tim-3-Ig was examined by SDS-PAGE and by Western blot 
using peroxidase conjugated anti-human Ig antibody and ECL 
detection  system.
    For the production of prokaryotic Tim-3-Ig protein, pIg20- 
Tim-3-Ig  was  transformed  into  BL21  Escherichia  coli ( I n v i -
t r o g e n ) .  T h e  b a c t e r i a  w e r e  a l l o w e d  t o  g r o w  i n  L u r i a  b r o t h 
media until an OD 600 of 0.8 was achieved. Expression of 
Tim-3-Ig  was  induced  with  addition  of 1mM  isopropyl-β -D 
(-)-thiogalactopyranoside (IPTG). Eight hours later the culture 
supernatant  was  harvested  and  Tim-3-Ig  was  purified.
Preparation of enriched mouse CD4
＋ T cells
For  enrichment  of  CD4
＋  T  cells,  spleen  and  lymph  nodes 
from 6∼8-week old mice were harvested and single cell sus-
pensions  were  prepared.  Lymphocytes  were  enriched  by 
Ficoll-Paque gradient centrifugation at 2,000 rpm for 20 min. 
CD4
＋  T  cells  were  enriched  by  positive  selection  with  the 
CD4
＋ T cell isolation kit (Miltenyi Biotec, Gladbach, Germa-
ny).
FACS analysis for binding activity of Tim-3-Ig protein
The  enriched  CD4
＋ T  c e l l s  w e r e  i n c u b a t e d  w i t h  T i m - 3 - I g ,  
FITC  conjugated  anti-CD4  mAb  (BD  Pharmingen)  and  PE 
conjugated  anti-CD25  mAb  (BD  Pharmingen)  at  4
oC  for  30 
min. After incubation, enriched CD4
＋ T cells were washed 
in PBS containing 2% BSA and then labeled with biotin-con-
jugated anti-human IgG Ab (BD biosciences) and Streptavi-
din-PerCP (BD biosciences). Stained cells were analyzed on 
a  BD  Vantage  system  (Becton-Dickinson  Co.).The Ligand Binding Activity of Recombinant Tim-3
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Figure 1. Comparison of Tim-3 amino- 
acid sequences of BALB/c with three 
different mouse strains. cDNA of Tim-3 
was cloned from activated splenocytes 
of BALB/c mouse, nucleotide sequences 
were analyzed and deduced amino acid 
sequences were shown. Accession num-
bers of BALB/c Tim-3 are AY553334.1 
for nucleotide sequences and AAS5931.1
for amino acid sequences. Accession 
numbers of C57BL/6, DBA/2 and AKR 
Tim-3 are BAE28574.1, AAL35776.1 
and AAL65156.1, respectively.
Figure 2. Analysis of Tim-3-Ig purified 
from CHO cell and E. coli culture. (A) 
Tim-3-Ig was purified from culture super-
natant of CHO cells transfected with 
pIRES2-EGFP-Tim-3-Ig using protein A 
affinity column chromatography and 
subjected to SDS-PAGE and Western 
blot using peroxidase conjugated anti- 
human IgG antibody and ECL detection 
system. (B) Tim-3-Ig was purified from 
culture supernatant of E. coli transform-
ed with pIg20-Tim-3-Ig and subjected to
SDS-PAGE and Western blot using pero-
xidase conjugated anti-human IgG anti-
body and ECL detection system.
RESULTS
Strain differences in Tim-3 amino acid sequences
First, cDNA of Tim-3 was cloned from activated splenocytes 
of BALB/c mouse and nucleotide sequences were analyzed. 
Then, Tim-3 amino acid sequences of BALB/c mouse were 
compared with those of C57BL/6 (gene bank accesion num-
ber: BAE28574.1), DBA/2 (AAL35776.1) and AKR (AAL65156. 
1) mice registered in gene bank (Fig. 1). In comparison with 
all  other  mouse  genotypes,  there  was  only  one  difference 
found at the 220th amino acid position in the linear sequence 
in Tim-3 of BALB/c. Compared with AKR, eight distinct ami-
no acids at the 24th, 25th, 27th, 28th, 43rd, 45th, 47th and 
220th sites in the linear amino acid sequence were observed 
in  Tim-3  of  BALB/c.
Tim-3-Ig fusion proteins purified from mammalian 
and bacterial cells
The cDNA fragment of Tim-3 extracellular domain and human 
IgG  heavy  chain  constant  region  were  inserted  into  a 
eukaryotic expression vector for the production of Tim-3-Ig 
fusion  protein.  CHO  cells  were  transfected  with  eukaryotic 
Tim-3-Ig  expression  plasmid  and  then  the  Tim-3-Ig  protein 
was purified from the culture supernatant by affinity column 
chromatography. Similarly, Tim-3-Ig was purified from E. coli 
transformed  with  prokaryotic  Tim-3-Ig  expression  vector. 
Purity  of  Tim-3-Ig  produced  in  each  cell  culture  type  was 
examined by SDS-PAGE analysis and Western blot (Fig. 2). 
Due  to  the  glycosylation  of  Tim-3,  the  band  for  Tim-3-Ig 
purified from CHO cells appeared above the 50 kD standard 
marker (Fig. 2A). Identification of this band as Tim-3-Ig was 
performed by Western blot using anti-human IgG Ab reacting 
with  fusion  partner. A band  of approximate 50  kD protein The Ligand Binding Activity of Recombinant Tim-3
Mi Jin Lee, et al.
61 IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 2 April 2009
Figure 4. Production of Tim-3-Ig N-gly-
cosylation mutants. (A) Schematic repre-
sentation and sequence analysis of Tim- 
3-Ig N-glycosylation mutants, N53Q and
N100Q. (B) Tim-3-Ig N-glycosylation 
mutants were purified from CHO cell 
culture using affinity column chromato-
graphy and subjected to SDS-PAGE an-
alysis and Western blot using peroxidase
conjugated anti-human Ig antibody and 
ECL detection system.
Figure 3. The binding activity of Tim-3-Ig to CD4
＋CD25
＋ T cells. 
Mouse CD4
+ T cells were labeled with FITC conjugated anti-CD4 Ab,
PE-conjugated anti-CD25 Ab and Tim-3-Ig purified either from CHO 
cells (A) or from E. coli (B). Subsequently, cells were stained with 
biotin-conjugated anti-human IgG Ab and Streptavidin-PerCP. Cells 
were gated on CD4 CD25 expression and the binding activity of 
Tim-3-Ig to these cells was analyzed by flow cytometry.
seen  in  the  Tim-3-Ig  lane  expressed  in  CHO  cells  on  SDS- 
PAGE appeared to be fetal bovine serum Ig heavy chain (Fig. 
2A).  Whereas  Tim-3-Ig  expressed  in  E.  coli w a s  s e e n  a s  
approximate a 45 kD band in the Western blot due to the 
lack of glycosylation (Fig. 2B). Tim-3-Ig expressed in E. coli 
was partially purified based on SDS-PAGE analysis (Fig. 2B). 
These  results  indicated  that  even  though  it  was  partially 
p u r i f i e d ,  T i m - 3 - I g  c o u l d  b e  u s e d  f o r  t e s t i n g  i t s  b i n d i n g  
reactivity to the ligands expressed on CD4
＋ CD25
＋ T cells 
since  its  ligand  binding  activity  would  be  revealed  with 
a n t i - h u m a n  I g G  A b  r e a c t i v e  t o  t h e  f u s i o n  p a r t n e r .
Similar binding reactivity of Tim-3-Ig fusion protein to 
CD4
＋ CD25
＋ T cells regardless of its cellular sources
CD4
＋ CD25
＋ T cells have been reported to express Tim-3 
ligand (5). To analyze ligand binding activity of Tim-3-Ig ex-
pressed in different cellular sources, enriched murine CD4
＋ 
T cells were incubated with Tim-3-Ig and subsequently, with 
anti-human  IgG  Ab  conjugated  with  immunofluorescence 
(Fig. 3). Enriched CD4
＋ T cells were gated on CD4
＋ CD25
＋ 
expression  (Fig.  3A  left  panel)  and  the  binding  activity  of 
Tim-3-Ig to these cells was analyzed by flow cytometry. Flow 
cytometric analysis showed that Tim-3-Ig expressed in CHO 
cells bound 41% to CD4
＋ CD25
＋ T cells (Fig. 3A right pan-
el). Further, Tim-3-Ig expressed in E. coli also bound to CD4
＋ 
CD25
＋ T cells (Fig. 3B). It should be mentioned that the mo-
l e c u l a r  c o n c e n t r a t i o n  o f  T i m - 3 - I g  u s e d  i n  F i g .  3 A  w a s  n o t  
same as that used in Fig. 3B. These results suggest that glyco-
sylation may not be critical to the binding activity of Tim-3-Ig 
to  the  ligand  on  CD4
＋ C D 2 5
＋ T  c e l l s .The Ligand Binding Activity of Recombinant Tim-3
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Figure 5. The binding activity of Tim-3-Ig N-glycosylation mutants to 
CD4
＋CD25
＋ T cells. Mouse CD4
＋ T cells were labeled with FITC 
conjugated anti-CD4 Ab, PE-conjugated anti-CD25 Ab and either 
Tim-3-Ig wild type or Tim-3-Ig N-glycosylation mutants. Subsequently,
these cells were incubated with biotin-conjugated anti-human IgG Ab
and Streptavidin-PerCP. Cells were gated on CD4 CD25 expression 
and the binding activity of Tim-3-Ig to these cells was analyzed by
flow cytometry.
Production of N-glycosylation mutant forms of Tim- 
3-Ig
The mucin domain of Tim-3 is not involved in ligand binding 
activity (2,5). N-glycosylation consensus sequence, Asn-Xaa- 
Ser/Thr, occurrs twice in Tim-3 IgV like domain. To further 
confirm the role of Tim-3 glycosylation in ligand binding ac-
tivity, mutants of two potential N-glycosylation sites of Tim-3 
IgV like domain were produced. Nucleotide sequences of eu-
k a r y o t i c  e x p r e s s i o n  v e c t o r s  f o r  N 5 3 Q ,  N 1 0 0 Q ,  a n d  d o u b l e  
mutant  N53/100Q  were  confirmed  respectively  (Fig.  4A). 
Then, these mutant forms expressed in CHO cells were puri-
fied and confirmed by SDS-PAGE and Western blot (Fig. 4B). 
Compared with wild type Tim-3-Ig, the molecular weight of 
the double mutant N53/100Q was significantly smaller. These 
results indirectly showed the absence of N-glycosylation on 
these  mutants.
Similar binding reactivity of Tim-3-Ig N-glycosylation 
mutants to CD4
＋ CD25
＋ T cells
Next  the  ligand  binding  activity  of  N-glycosylation  mutant 
f o r m s  w a s  e x a m i n e d  ( F i g .  5 ) .  T h e  c o n c e n t r a t i o n  o f  e a c h  
Tim-3-Ig form was adjusted to 0.75 μM. Since the concen-
t r a t i o n  o f  T i m - 3 - I g  w a s  m u c h  l o w e r  t h a n  t h a t  u s e d  i n  F i g .  
3A,  the  binding  activity  of  wild  Tim-3-Ig  was  less  evident. 
However, as expected, there was no difference in the binding 
activity between any of the Tim-3-Ig N-glycosylation mutant 
forms  and  wild  type  Tim-3-Ig  implying  that  N-glycosylation 
of Tim-3 IgV like domain may not affect ligand binding activ-
ity  of  Tim-3.
DISCUSSION
Although  the  studies  regarding  immunomodulatory  function 
of  Tim-3  have  been  accumulated,  the  interaction  of  Tim-3 
with its ligand has not been well studied. In this study, the 
binding  activity  of  Tim-3-Ig  fusion  protein  expressed  either 
in CHO cells or in E. coli to its ligand-expressing CD4
＋ CD25
＋ 
T  cells  was  evaluated,  and  the  role  of  N-glycosylation  of 
Tim-3  in  its  ligand  interaction  was  investigated.
    Supporting  previous  reports  (2),  Tim-3-Ig  expressed  in 
CHO cells showed binding activity to CD4
＋ CD25
＋ T cells. 
Also, bacterially expressed Tim-3-Ig bound to these cells. Like 
our  results,  a recent report  by Cao  et  al. shows bacterially 
expressed Tim-3 IgV tetramer bound to Foxp3
＋ T cells and 
suggests a second ligand for Tim-3 other than galectin-9 (10). 
In line with these findings, N-glycosylation mutants of Tim-3- 
Ig bound CD4
＋ CD25
＋ T cells comparable to the wild type 
Tim-3-Ig. Our results suggest that glycosylation may not be 
required for the interaction of Tim-3 with its ligands on CD4
＋ 
CD25
＋ T  c e l l s .  
    Although  bacterially  expressed  Tim-3-Ig  showed  binding 
activity  to  CD4
＋ C D 2 5
＋  T  cells,  it  should  be  addressed 
whether its biological activity is same as Tim-3-Ig expressed 
i n  m a m m a l i a n  c e l l s .  T h e  r e a s o n s  a r e  a s  f o l l o w s .  F i r s t ,  g a -
lectin-9,  a  known  Tim-3  ligand,  requires  glycosylation  of 
Tim-3  for  its  binding  (8).  Second,  until  now  Tim-3-Ig  ex-
pressed in eukaryotic cells has been used in functional stu-
dies.  Third,  the  stabilities  of  bacterially  expressed  Tim-3-Ig 
and  Tim-3-Ig  expressed  in  eukaryotic  cells  have  not  been 
compared.  Glycosylation  may  confer  stability  on  Tim-3-Ig. 
  F o r  t h e  t h e r a p e u t i c  u s e  o f  T I M - 3 - I g ,  c o n v e n i e n t  m a s s i v e  
production of TIM-3-Ig will be desirable. In spite of the gen-
eral advantages of bacterial expression systems such as low 
cost,  our  bacterial  expression  system  revealed  critical  dis-
advantages in the purification step. Even though we tried cati-
on  exchange  column  chromatography,  the  purity  did  not 
greatly  improved  (data  not shown).  In  terms  of  purity,  the 
mammalian  expression  system  was  better  for  Tim-3-Ig 
production. 
    In this study, BALB/c Tim-3 cDNA and deduced amino acid 
sequences  were  identified.  Compared  with  Tim-3  of  other 
murine genotypes, BALB/c Tim-3 differs at 220th amino acid 
position.  BALB/c  Tim-3  showed  8  amino  acid  differences The Ligand Binding Activity of Recombinant Tim-3
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compared  to  AKR  Tim-3.  It  may  be  interesting  to  study 
whether these differences have an effect on the function of 
Tim-3.
    To conclude, our results suggest that Tim-3-Ig fusion pro-
tein may bind to CD4
＋ CD25
＋ T cells without need to be 
glcosylated  including  N-glycosylation  of  IgV  domain.  The 
contribution of glycosylation to the stability and function of 
Tim-3  remains  to  be  revealed.
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